| Primary |
| Hypertension |
37.5% |
| Anxiety |
12.5% |
| Arrhythmia |
12.5% |
| Mental Impairment |
12.5% |
| Prophylaxis |
12.5% |
| Prostatic Adenoma |
12.5% |
|
|
| Secondary |
| Product Used For Unknown Indication |
26.3% |
| Drug Use For Unknown Indication |
21.1% |
| Hypertension |
19.3% |
| Type 2 Diabetes Mellitus |
6.6% |
| Hypertensive Cardiomyopathy |
3.5% |
| Pain |
3.1% |
| Anxiety |
2.2% |
| Atrial Fibrillation |
1.8% |
| Epilepsy |
1.8% |
| Essential Hypertension |
1.8% |
| Extrapyramidal Disorder |
1.8% |
| Micturition Disorder |
1.8% |
| Prophylaxis |
1.8% |
| Arrhythmia |
1.3% |
| Dyslipidaemia |
1.3% |
| Mental Impairment |
1.3% |
| Analgesic Therapy |
0.9% |
| Benign Neoplasm Of Prostate |
0.9% |
| Benign Prostatic Hyperplasia |
0.9% |
| Hypothyroidism |
0.9% |
|
| Renal Failure Acute |
20.0% |
| Vomiting |
11.1% |
| Drug Interaction |
6.7% |
| Renal Failure |
6.7% |
| Hodgkin's Disease |
4.4% |
| Hyperlactacidaemia |
4.4% |
| Interstitial Lung Disease |
4.4% |
| Malaise |
4.4% |
| Neural Tube Defect |
4.4% |
| Orthostatic Hypotension |
4.4% |
| Pancreatic Enzymes Increased |
4.4% |
| Vitamin D Deficiency |
4.4% |
| Weight Decreased |
4.4% |
| Altered State Of Consciousness |
2.2% |
| Blood Creatine Increased |
2.2% |
| Blood Pressure Decreased |
2.2% |
| Blood Pressure Increased |
2.2% |
| Blood Urea Increased |
2.2% |
| Dehydration |
2.2% |
| Dermatitis Bullous |
2.2% |
|
| Concomitant |
| Drug Use For Unknown Indication |
38.9% |
| Hypertension |
20.7% |
| Product Used For Unknown Indication |
15.9% |
| Rheumatoid Arthritis |
4.4% |
| Hiv Infection |
2.1% |
| Multiple Myeloma |
2.0% |
| Type 2 Diabetes Mellitus |
1.6% |
| Pain |
1.6% |
| Prophylaxis |
1.5% |
| Palindromic Rheumatism |
1.3% |
| Cardiac Disorder |
1.1% |
| Diabetes Mellitus |
1.1% |
| Dyslipidaemia |
1.1% |
| Thrombosis Prophylaxis |
1.1% |
| General Anaesthesia |
1.0% |
| Hypertonia |
1.0% |
| Non-small Cell Lung Cancer |
1.0% |
| Arrhythmia |
0.9% |
| Asthma |
0.9% |
| Atrial Fibrillation |
0.9% |
|
| Renal Failure Acute |
17.1% |
| Vomiting |
9.9% |
| Pyrexia |
8.1% |
| Thrombocytopenia |
8.1% |
| Pulmonary Embolism |
7.2% |
| Gastrointestinal Haemorrhage |
3.6% |
| General Physical Health Deterioration |
3.6% |
| Hyponatraemia |
3.6% |
| Lung Disorder |
3.6% |
| Renal Failure |
3.6% |
| Therapeutic Response Decreased |
3.6% |
| Urinary Retention |
3.6% |
| Venous Thrombosis |
3.6% |
| Ventricular Hypertrophy |
3.6% |
| Weight Increased |
3.6% |
| Cytolytic Hepatitis |
2.7% |
| Death |
2.7% |
| Electrocardiogram Qt Prolonged |
2.7% |
| Fall |
2.7% |
| Hypertension |
2.7% |
|
| Interacting |
|
| Syncope |
50.0% |
| Hypotension |
25.0% |
| Vomiting |
25.0% |
|
